Dr. Socinski on Improvements to Immunotherapy for Lung Cancer

Mark A. Socinski, MD
Published: Tuesday, Apr 25, 2017



Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses potential improvements to immunotherapy regimens for patients with lung cancer.

One of the ways immunotherapy can be improved is by the selection of the patients, explains Socinski. There is evidence that demonstrates that patients who strongly stain for PD-L1 have better outcomes.

There is also some encouraging data from the KEYNOTE-021 trial for combining immunotherapy with chemotherapy. Combining immunotherapy agents could have potential but it creates the risk for higher toxicities, states Socinski.
 


Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses potential improvements to immunotherapy regimens for patients with lung cancer.

One of the ways immunotherapy can be improved is by the selection of the patients, explains Socinski. There is evidence that demonstrates that patients who strongly stain for PD-L1 have better outcomes.

There is also some encouraging data from the KEYNOTE-021 trial for combining immunotherapy with chemotherapy. Combining immunotherapy agents could have potential but it creates the risk for higher toxicities, states Socinski.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x